DK3848028T3 - METHODS OF TREATMENT OF EYE DISORDERS - Google Patents

METHODS OF TREATMENT OF EYE DISORDERS Download PDF

Info

Publication number: DK3848028T3
Authority: DK; Denmark
Prior art keywords: treatment; methods; eye disorders; disorders; eye
Prior art date: 2014-10-20

Application number

DK20212556.3T

Other languages

Danish (da)

Other versions

DK3848028T5 (en

Inventor

Douglas Michael Ackermann Jr

James Loudin

Kenneth J Mandell

Original Assignee

Oyster Point Pharma Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-10-20

Filing date

2015-10-19

Publication date

2024-08-26

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55748136&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3848028(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2015-10-19 Application filed by Oyster Point Pharma Inc filed Critical Oyster Point Pharma Inc

2024-08-26 Publication of DK3848028T3 publication Critical patent/DK3848028T3/en

2025-01-20 Application granted granted Critical

2025-01-20 Publication of DK3848028T5 publication Critical patent/DK3848028T5/en

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Otolaryngology (AREA)
Pulmonology (AREA)
Ophthalmology & Optometry (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Emergency Medicine (AREA)

DK20212556.3T 2014-10-20 2015-10-19 METHODS FOR TREATING EYE DISORDERS DK3848028T5 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201462066280P	2014-10-20	2014-10-20
US201562100844P	2015-01-07	2015-01-07
EP15852340.7A EP3209295B2 (en)	2014-10-20	2015-10-19	Methods of treating ocular conditions

Publications (2)

Publication Number	Publication Date
DK3848028T3 true DK3848028T3 (en)	2024-08-26
DK3848028T5 DK3848028T5 (en)	2025-01-20

Family

ID=55748136

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK15852340.7T DK3209295T4 (en)	2014-10-20	2015-10-19	METHODS OF TREATMENT OF EYE DISORDERS
DK20212556.3T DK3848028T5 (en)	2014-10-20	2015-10-19	METHODS FOR TREATING EYE DISORDERS

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
DK15852340.7T DK3209295T4 (en)	2014-10-20	2015-10-19	METHODS OF TREATMENT OF EYE DISORDERS

Country Status (21)

Country	Link
US (14)	US9504645B2 (en)
EP (3)	EP3848028B9 (en)
JP (3)	JP6873906B2 (en)
KR (2)	KR102511955B1 (en)
CN (3)	CN107106542B (en)
AU (2)	AU2015336216B2 (en)
BR (2)	BR122022025737B1 (en)
CA (1)	CA2965129C (en)
DK (2)	DK3209295T4 (en)
EA (1)	EA035335B1 (en)
ES (2)	ES2848977T5 (en)
FI (1)	FI3848028T3 (en)
IL (3)	IL293188B2 (en)
MX (2)	MX392383B (en)
MY (1)	MY186870A (en)
PH (1)	PH12017500602A1 (en)
PL (1)	PL3848028T3 (en)
PT (2)	PT3848028T (en)
SG (2)	SG11201703135XA (en)
WO (1)	WO2016064759A1 (en)
ZA (1)	ZA201703467B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL293188B2 (en)	2014-10-20	2025-06-01	Oyster Point Pharma Inc	Varenicline compound for use as a medication for treating dry eye, increasing tear production and treating eye discomfort and a pramipexole preparation containing varenicline
WO2017177024A1 (en) *	2016-04-07	2017-10-12	Oyster Point Pharma, Inc.	Methods of treating ocular conditions
WO2020014217A1 (en) *	2018-07-10	2020-01-16	Oyster Point Pharma, Inc.	Methods of treating ocular conditions
WO2020014232A1 (en)	2018-07-10	2020-01-16	Oyster Point Pharma, Inc.	Combinations of positive allosteric modulators and nicotinic acetylcholine receptor agonists for treating ocular conditions
WO2021222230A1 (en)	2020-04-28	2021-11-04	Oyster Point Pharma, Inc.	Local administration of nicotinic acetylcholine receptor agonists for the inhibition of coronavirus infections
WO2025037323A1 (en) *	2023-08-12	2025-02-20	Pavan Kumar Kothapuvari	Pharmaceutical compositions for treatment of dry eye disease and associated disorders
DE102023208057A1 (en) *	2023-08-23	2025-02-27	Ursapharm Arzneimittel Gmbh	OPHTHALMOLOGICAL COMPOSITION CONTAINING AT LEAST ONE NICOTINE ACETYLCHOLINE RECEPTOR AGONIST FOR TOPICAL APPLICATION TO THE EYE IN THE PREVENTION OR TREATMENT OF EYE INFLAMMATIONS

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6277855B1 (en)	2000-04-21	2001-08-21	Inspire Pharmaceuticals, Inc.	Method of treating dry eye disease with nicotinic acetylcholine receptor agonists
US20030008892A1 (en)	2001-07-09	2003-01-09	Pfizer Inc.	Pharmaceutical composition and method of modulating cholinergic function in a mammal
CA2468705A1 (en)	2001-11-29	2003-06-05	Pfizer Products Inc.	Succinic acid salts of 5,8,14-triazatetracyclo'10.3.1.0<2,11>.0<4,9>-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof
WO2004039366A1 (en)	2002-11-01	2004-05-13	Pharmacia & Upjohn Company Llc	Nicotinic acetylcholine agonists in the treatment of glaucoma and retinal neuropathy
US20060270592A1 (en) *	2004-03-19	2006-11-30	Ophthalmic Research Associates, Inc.	Use of neurotransmitters and neuropeptides for the treatment of dry eye diseases and related conditions
JP2008516942A (en)	2004-10-15	2008-05-22	ファイザー・プロダクツ・インク	Compositions and methods for intranasal, buccal, sublingual and pulmonary delivery of varenicline
EP1827373B1 (en) *	2004-11-09	2008-12-03	Novagali Pharma SA	Ophthalmic emulsions containing prostaglandins
AU2006226509A1 (en) *	2005-03-22	2006-09-28	Niconovum Ab	Use of an artificial sweetener to enhance absorption of nicotine
US20110086086A1 (en)	2005-07-26	2011-04-14	Pfizer Inc	Transdermal system for varenicline
ATE458491T1 (en)	2005-08-26	2010-03-15	Univ Leland Stanford Junior	METHOD FOR TREATING HEADACHE BY ADMINISTRATION OF OXYTOCIN
EP2664337B1 (en)	2005-09-27	2019-08-14	TissueTech, Inc.	Amniotic membrane preparations and purified compositions and methods of use
TWI404532B (en) *	2006-11-02	2013-08-11	Targacept Inc	Nicotinic acetylcholine receptor sub-type selective amides of diazabicycloalkanes
US20080132475A1 (en) *	2006-12-05	2008-06-05	Charles Gerald Connor	Treatment for dry eye
BRPI0808634A2 (en) *	2007-02-02	2014-08-05	Pfizer Prod Inc	TRICYCLIC COMPOUNDS, COMPOSITIONS AND METHODS.
EP2322167A1 (en) *	2007-04-02	2011-05-18	Parkinson's Institute	Methods and Compositions for Reduction of Side Effects of Therapeutic Treatments
US20090093446A1 (en)	2007-10-05	2009-04-09	Winston Laboratories, Inc.	Method for alleviating keratoconjunctivitis sicca
CL2008003507A1 (en) *	2007-11-26	2009-11-27	Neuroderm Ltd	Pharmaceutical composition comprising nicotine and a nicotinic acetylcholine receptor (nachr) opipramol desensitization inhibitor; pharmaceutical kit; medical device; and use to treat a disease or disorder of the central or peripheral nervous system.
US20090215787A1 (en)	2008-02-22	2009-08-27	Mai De Ltd.	Preparations of new polymorphic forms of varenicline tartrate
KR20100122508A (en)	2008-03-05	2010-11-22	타가셉트 인코포레이티드	Nicotinic acetylcholine receptor sub-type selective amides of diazabicycloalkanes
WO2010028033A1 (en)	2008-09-05	2010-03-11	Targacept, Inc.	Amides of diazabicyclooctanes and uses thereof
WO2010028011A1 (en)	2008-09-05	2010-03-11	Targacept, Inc.	Amides of diazabicyclononanes and uses thereof
US9145396B2 (en)	2008-12-01	2015-09-29	Targacept, Inc.	Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3ylvinyl)pyrimidine
RU2533819C2 (en)	2008-12-01	2014-11-20	Таргасепт, Инк.	Synthesis and new saline forms of (r)-5-((e)-2-(pyrrolidin-3-ylvinyl)pyrimidine
US20110274628A1 (en)	2010-05-07	2011-11-10	Borschke August J	Nicotine-containing pharmaceutical compositions
US8821457B2 (en) *	2010-09-08	2014-09-02	Johnson & Johnson Vision Care, Inc.	Punctal plug containing drug formulation
EP2720719A4 (en) *	2011-06-15	2015-12-09	Glaxosmithkline Ip No 2 Ltd	Method of selecting therapeutic indications
CA2840480A1 (en) *	2011-06-30	2013-01-03	Toray Industries, Inc.	Antipruritic agent
JO3766B1 (en) *	2011-10-20	2021-01-31	Novartis Ag	alpha 7 nicotinic acetylcholine receptor activator
WO2013080196A1 (en) *	2011-11-30	2013-06-06	D.E.S. Diagnostics Ltd.	Dry eye diagnostic
ES2426517B1 (en) *	2012-04-20	2014-05-14	Genetracer Biotech S.L	Method to predict the safety of a drug treatment
EP2968368B1 (en)	2013-03-15	2017-08-09	Glia LLC	Cranial delivery of pharmaceuticals
CN108744272A (en)	2013-04-19	2018-11-06	奥库利维公司	Nose stimulating apparatus and method
IL293188B2 (en)	2014-10-20	2025-06-01	Oyster Point Pharma Inc	Varenicline compound for use as a medication for treating dry eye, increasing tear production and treating eye discomfort and a pramipexole preparation containing varenicline
WO2017177024A1 (en)	2016-04-07	2017-10-12	Oyster Point Pharma, Inc.	Methods of treating ocular conditions
WO2020014232A1 (en)	2018-07-10	2020-01-16	Oyster Point Pharma, Inc.	Combinations of positive allosteric modulators and nicotinic acetylcholine receptor agonists for treating ocular conditions
WO2020014217A1 (en)	2018-07-10	2020-01-16	Oyster Point Pharma, Inc.	Methods of treating ocular conditions

2015
- 2015-10-19 IL IL293188A patent/IL293188B2/en unknown
- 2015-10-19 ES ES15852340T patent/ES2848977T5/en active Active
- 2015-10-19 WO PCT/US2015/056273 patent/WO2016064759A1/en not_active Ceased
- 2015-10-19 EP EP20212556.3A patent/EP3848028B9/en active Active
- 2015-10-19 CN CN201580067940.5A patent/CN107106542B/en active Active
- 2015-10-19 PT PT202125563T patent/PT3848028T/en unknown
- 2015-10-19 FI FIEP20212556.3T patent/FI3848028T3/en active
- 2015-10-19 MY MYPI2017701382A patent/MY186870A/en unknown
- 2015-10-19 SG SG11201703135XA patent/SG11201703135XA/en unknown
- 2015-10-19 SG SG10202011669PA patent/SG10202011669PA/en unknown
- 2015-10-19 DK DK15852340.7T patent/DK3209295T4/en active
- 2015-10-19 EA EA201790893A patent/EA035335B1/en unknown
- 2015-10-19 BR BR122022025737-2A patent/BR122022025737B1/en active IP Right Grant
- 2015-10-19 US US14/887,259 patent/US9504645B2/en active Active
- 2015-10-19 BR BR112017008097-4A patent/BR112017008097B1/en active IP Right Grant
- 2015-10-19 IL IL318427A patent/IL318427A/en unknown
- 2015-10-19 EP EP15852340.7A patent/EP3209295B2/en active Active
- 2015-10-19 EP EP24171017.7A patent/EP4413974A3/en active Pending
- 2015-10-19 ES ES20212556T patent/ES2986830T3/en active Active
- 2015-10-19 AU AU2015336216A patent/AU2015336216B2/en active Active
- 2015-10-19 KR KR1020177013534A patent/KR102511955B1/en active Active
- 2015-10-19 CN CN202010304375.2A patent/CN111956803B/en active Active
- 2015-10-19 KR KR1020237009057A patent/KR102601505B1/en active Active
- 2015-10-19 IL IL251769A patent/IL251769B/en unknown
- 2015-10-19 DK DK20212556.3T patent/DK3848028T5/en active
- 2015-10-19 JP JP2017539528A patent/JP6873906B2/en active Active
- 2015-10-19 US US14/887,248 patent/US9597284B2/en active Active
- 2015-10-19 CN CN202010304809.9A patent/CN111956650B/en active Active
- 2015-10-19 MX MX2017005064A patent/MX392383B/en unknown
- 2015-10-19 PT PT158523407T patent/PT3209295T/en unknown
- 2015-10-19 US US14/887,243 patent/US9504644B2/en active Active
- 2015-10-19 US US14/887,253 patent/US9532944B2/en active Active
- 2015-10-19 CA CA2965129A patent/CA2965129C/en active Active
- 2015-10-19 PL PL20212556.3T patent/PL3848028T3/en unknown
2017
- 2017-02-01 US US15/422,382 patent/US10456396B2/en active Active
- 2017-03-31 PH PH12017500602A patent/PH12017500602A1/en unknown
- 2017-04-19 MX MX2022005888A patent/MX2022005888A/en unknown
- 2017-05-19 ZA ZA2017/03467A patent/ZA201703467B/en unknown
2019
- 2019-09-10 US US16/566,237 patent/US11224598B2/en active Active
2020
- 2020-08-06 AU AU2020213351A patent/AU2020213351B2/en active Active
- 2020-11-20 JP JP2020193269A patent/JP7257371B2/en active Active
2021
- 2021-12-06 US US17/543,505 patent/US11903941B2/en active Active
2022
- 2022-12-20 JP JP2022202809A patent/JP7502404B2/en active Active
2023
- 2023-03-23 US US18/125,562 patent/US11903943B2/en active Active
- 2023-03-23 US US18/125,551 patent/US11911380B2/en active Active
- 2023-03-23 US US18/125,517 patent/US11903942B2/en active Active
2024
- 2024-01-26 US US18/423,908 patent/US20240173318A1/en not_active Abandoned
2025
- 2025-04-03 US US19/169,843 patent/US20250255865A1/en active Pending
- 2025-04-03 US US19/169,836 patent/US20250275963A1/en active Pending
- 2025-04-03 US US19/169,817 patent/US20250235449A1/en active Pending

Also Published As

Publication number	Publication date
US9504644B2 (en)	2016-11-29
MX2017005064A (en)	2018-02-23
IL318427A (en)	2025-03-01
US11903943B2 (en)	2024-02-20
US20170239244A1 (en)	2017-08-24
US20200246336A1 (en)	2020-08-06
IL293188B1 (en)	2025-02-01
JP2017531044A (en)	2017-10-19
CN107106542A (en)	2017-08-29
PH12017500602A1 (en)	2017-09-04
MX2022005888A (en)	2022-06-14
US11903941B2 (en)	2024-02-20
PL3848028T3 (en)	2024-11-18
ES2848977T5 (en)	2024-06-06
US20160106665A1 (en)	2016-04-21
IL293188A (en)	2022-07-01
KR20230042144A (en)	2023-03-27
MX392383B (en)	2025-03-24
CA2965129A1 (en)	2016-04-28
US20160106745A1 (en)	2016-04-21
US9504645B2 (en)	2016-11-29
KR20170086040A (en)	2017-07-25
DK3848028T5 (en)	2025-01-20
US9532944B2 (en)	2017-01-03
US20250235449A1 (en)	2025-07-24
AU2015336216B2 (en)	2020-05-21
US20230226052A1 (en)	2023-07-20
IL251769B (en)	2022-06-01
WO2016064759A1 (en)	2016-04-28
EP3848028A1 (en)	2021-07-14
EA201790893A1 (en)	2018-01-31
EP3848028B9 (en)	2024-10-16
ES2986830T3 (en)	2024-11-12
EP3209295A4 (en)	2018-05-23
DK3209295T3 (en)	2021-03-01
US20250255865A1 (en)	2025-08-14
US11224598B2 (en)	2022-01-18
CN111956650B (en)	2024-06-04
EP4413974A2 (en)	2024-08-14
SG11201703135XA (en)	2017-05-30
US11911380B2 (en)	2024-02-27
AU2015336216A1 (en)	2017-06-08
US10456396B2 (en)	2019-10-29
JP7502404B2 (en)	2024-06-18
US9597284B2 (en)	2017-03-21
SG10202011669PA (en)	2020-12-30
JP2021038250A (en)	2021-03-11
US20230226054A1 (en)	2023-07-20
BR112017008097B1 (en)	2023-03-28
EP4413974A3 (en)	2024-10-09
CN111956803A (en)	2020-11-20
JP6873906B2 (en)	2021-05-19
MY186870A (en)	2021-08-26
KR102511955B1 (en)	2023-03-22
EP3848028B1 (en)	2024-05-29
CN107106542B (en)	2020-05-08
EP3209295B2 (en)	2023-12-06
PT3848028T (en)	2024-09-20
US20230226053A1 (en)	2023-07-20
JP2023024574A (en)	2023-02-16
BR112017008097A2 (en)	2018-02-20
EA035335B1 (en)	2020-05-28
CN111956803B (en)	2025-10-31
EP3209295A1 (en)	2017-08-30
US20160106746A1 (en)	2016-04-21
US20220233528A1 (en)	2022-07-28
DK3209295T4 (en)	2024-02-26
CA2965129C (en)	2024-03-12
BR122022025737B1 (en)	2023-12-26
FI3848028T3 (en)	2024-08-21
IL251769A0 (en)	2017-06-29
EP3209295B1 (en)	2020-12-09
AU2020213351B2 (en)	2023-04-06
CN111956650A (en)	2020-11-20
IL293188B2 (en)	2025-06-01
ES2848977T3 (en)	2021-08-13
US20160106744A1 (en)	2016-04-21
US20240173318A1 (en)	2024-05-30
ZA201703467B (en)	2023-12-20
US20250275963A1 (en)	2025-09-04
PT3209295T (en)	2021-02-05
JP7257371B2 (en)	2023-04-13
US11903942B2 (en)	2024-02-20
KR102601505B1 (en)	2023-11-14
AU2020213351A1 (en)	2020-08-27

Publication	Publication Date	Title
DK3851537T3 (en)	2024-03-18	TREATMENT OF HYPERBILIRUBINAMIA
DK3450553T3 (en)	2020-02-10	MRNA THERAPY FOR TREATMENT OF EYE DISEASES
DK3212233T3 (en)	2020-07-27	COMBINATION THERAPY FOR TREATMENT OF DISEASE
DK3718507T3 (en)	2024-10-28	DEVICES FOR TREATMENT OF LOWER EXTREMITY VASCULATION
DK3171928T3 (en)	2020-05-18	STIMULATION PATTERNS FOR TREATMENT OF DRY EYES
DK3185876T3 (en)	2022-10-31	COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
DK3240612T3 (en)	2021-01-18	PROCEDURES FOR THE TREATMENT OF RHINTH DISEASES
DK3137169T3 (en)	2022-02-14	INHIBITORIES OF LYSIN-SPECIFIC DEMETHYLASE-1
DK3125875T3 (en)	2023-07-24	INHALABLE RAPAMYCINFORMULATION FOR THE TREATMENT OF AGING-RELATED CONDITIONS
DK3265085T3 (en)	2022-10-03	METHODS OF TREATMENT OF ABNORMAL INVOLUNTARY MOVEMENT DISORDERS
DK3777855T3 (en)	2023-01-09	METHODS OF TREATMENT OF FIBROTIC DISEASES
DK3288577T3 (en)	2022-01-10	ADIPONECTIN PEPTIDOMIMETICS FOR THE TREATMENT OF EYE DISORDERS
DK3142664T3 (en)	2020-03-09	COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSTICATION OF EYE DISEASES
DK3132009T3 (en)	2023-02-06	COURSE OF ACTION
DK3283210T3 (en)	2021-11-22	COURSE OF ACTION
DK3164394T3 (en)	2020-05-04	GLS1 INHIBITORS FOR TREATMENT OF DISEASES
PL3393468T3 (en)	2023-01-23	METHODS OF TREATING IMMUNODEFICIENCE
DK3237621T5 (en)	2024-10-14	VARIANTS OF HUMAN ALPHA-GALACTOSIDASE
DK3307267T3 (en)	2019-07-01	TREATMENT OF MULTIPLE SHELLOSIS
DK3209295T4 (en)	2024-02-26	METHODS OF TREATMENT OF EYE DISORDERS
DK3192524T3 (en)	2022-02-14	HGF PREPARATION SUITABLE FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
DK3439661T3 (en)	2021-10-18	PROCEDURES FOR THE TREATMENT OF EYE DISORDERS
DK3151814T3 (en)	2019-11-04	TREATMENT OF A SKIN LESSON
DK3143123T3 (en)	2020-02-10	MICRORNA-INDUCTION OF CARDIOLOGICAL REGENERATION
DK3297619T3 (en)	2022-08-15	Therapeutic uses of L-4-chlorokynurenine